ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR...

ProMetic presents preclinical data for prostate and pancreatic cancer at the
AACR Meeting
Three Developmental Compounds Show Early Promise

MONTREAL, April 17 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.
(TSX:PLI) ("ProMetic") announced results of three compounds in preclinical
studies for prostate and pancreatic cancer at the American Association for
Cancer Research ("AACR") Annual Meeting 2008 being held in San Diego this
week.
Data on PBI-1737, PBI-0110 and PBI-1308 were presented in poster sessions
as follows:
Dr. Mouna Lagroui, ProMetic's Research Scientist, presented data on
PBI-1737 in prostate cancer. Results demonstrated that PBI-1737 displayed
significant antitumor activity in human prostate cancer both in vitro and in
vivo. The in vivo study demonstrated a significant reduction in tumor volume
both alone (p < 0.05) and in combination with cyclophosphamide (p < 0.01).
Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology,
presented preclinical data on the PBI-0110 alone and in combination with
gemcitabine in intradermal and orthotopic pancreatic cancer. The study showed
that PBI-0110 alone significantly inhibited pancreatic tumor growth in mouse
models by as much as 58 percent (p < 0.05) after 44 days. The study also
demonstrated a dose dependent inhibition of tumor growth, with the 400mg/kg
dose being the most effective, inhibiting growth by nearly 40 percent after 25
days (p < 0.05). Combination therapy of 100mg/kg PBI-0110 and gemcitabine
demonstrated similar efficacy. Finally, the study demonstrated increased
survival in mice that received the combination therapy of PBI-0110 200mg/kg
and gemcitabine.
Finally, Dr. Brigitte Grouix, ProMetic research scientist, presented data
on PBI-1308, which demonstrated a reduction of inflammation and cancer cell
proliferation through inhibition of NF-kappaB in prostate cancer and
inhibition of TNF-alpha, and inflammatory cytokine.
"We continue to be very proud of the progress our compounds are making in
early-stage cancer research," said Pierre Laurin, president and CEO of
ProMetic Life Sciences, Inc. "We are assembling a broad pipeline of promising
candidates for various cancers, which augments PBI-1402, our lead compound
which has shown compelling human data for the treatment of
chemotherapy-induced anemia."
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and marketing of
a variety of commercial applications derived from its proprietary Mimetic
Ligand(TM) technology. This technology is used in large-scale purification of
biologics and the elimination of pathogens. ProMetic is also active in
therapeutic drug development with the mission to bring to market effective,
innovative, lower cost, less toxic products for the treatment of hematology
and cancer. Its drug discovery platform is focused on replacing complex,
expensive proteins with synthetic "drug-like" protein mimetics. Headquartered
in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and
Canada, manufacturing facilities in the U.K. and business development
activities in the U.S., Europe, Asia and in the Middle-East.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks
affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to,
ProMetic's ability to develop, manufacture, and successfully commercialize
value-added pharmaceutical products, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of ProMetic to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of ProMetic's
Annual Information Form for the year ended December 31, 2007, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a
result of future events or for any other reason, unless required by applicable
securities laws and regulations.
SOURCE PROMETIC LIFE SCIENCES INC.

Company Inquiries: Pierre Laurin, President and CEO, ProMetic Life Sciences
Inc., (514) 341-2115, p.laurin@prometic.com; Anne Leduc, Manager, Investor
Relations & Communications, ProMetic Life Sciences Inc., (514) 341-2115,
a.leduc@prometic.com; Dominic Sicotte, Echoes Financial Network Inc., (514)
842-9551, dsicotte@echoesfinancial.com; Investor Relations: Bruce Voss,
Lippert/Heilshorn & Associates, (310) 691-7100, BVoss@lhai.com; Kim Golodetz,
Lippert/Heilshorn & Associates, (212) 838-3777, KGolodetz@lhai.com; Media
Relations: Jules Abraham, Lippert/Heilshorn & Associates, (212) 838-3777,
JAbraham@lhai.com